Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 814,913
  • Shares Outstanding, K 85,064
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,000 K
  • EBIT $ -55 M
  • EBITDA $ -55 M
  • 60-Month Beta 0.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.20

Options Overview Details

View History
  • Implied Volatility 63.08% ( -15.42%)
  • Historical Volatility 69.89%
  • IV Percentile 19%
  • IV Rank 27.83%
  • IV High 174.63% on 07/30/24
  • IV Low 20.06% on 05/01/24
  • Put/Call Vol Ratio 0.26
  • Today's Volume 97
  • Volume Avg (30-Day) 1,486
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 58,805
  • Open Int (30-Day) 62,095

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.26 +32.16%
on 04/09/25
9.80 -2.09%
on 04/23/25
+0.88 (+10.03%)
since 03/28/25
3-Month
7.26 +32.16%
on 04/09/25
10.20 -5.93%
on 03/20/25
-0.10 (-1.08%)
since 01/29/25
52-Week
3.51 +173.36%
on 06/14/24
14.44 -33.55%
on 12/26/24
+5.95 (+162.88%)
since 04/29/24

Most Recent Stories

More News
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

AVXL : 9.63 (+0.52%)
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

AVXL : 9.63 (+0.52%)
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

AVXL : 9.63 (+0.52%)
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

AVXL : 9.63 (+0.52%)
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

AVXL : 9.63 (+0.52%)
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

AVXL : 9.63 (+0.52%)
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

AVXL : 9.63 (+0.52%)
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

AVXL : 9.63 (+0.52%)
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

AVXL : 9.63 (+0.52%)
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

AVXL : 9.63 (+0.52%)

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

3rd Resistance Point 10.15
2nd Resistance Point 9.93
1st Resistance Point 9.76
Last Price 9.63
1st Support Level 9.37
2nd Support Level 9.15
3rd Support Level 8.98

See More

52-Week High 14.44
Fibonacci 61.8% 10.27
Last Price 9.63
Fibonacci 50% 8.98
Fibonacci 38.2% 7.69
52-Week Low 3.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar